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Introduction: Preclinical cardiotoxicity has been observed for at least 3 different HCV NS3 
protease inhibitors. We previously described the ultrarapid clinical and ultrastructural 
mitochondrial cardiotoxicity after 4 doses of BILN2061 in mice. As proteases are important in the 
biogenesis of mitochondria, a class toxicity of NS3 protease inhibitors can be feared. 
Methods:  Single and multiple dose BILN2061 toxicity studies were performed at 30 and 150 
mg/kg BID intraperitoneally for 7 days in several mouse strains. Vehicle-dosed animals were 
used as controls. Peak and trough plasma levels were determined with a HPLC-UV method. The 
ultrastructural and functional integrity of cardiomyocytes was analysed with electron microscopy 
and surface electrocardiography.  The activity of cardiac mitochondrial oxidative phosphorylation 
complexes was determined with Blue Native polyacrylamide gel electrophoresis and confirmed 
with spectrophotometry. 
Results:  BILN2061 at 150 mg/kg BID is 100% lethal within 2 days in all mouse strains tested, 
while 30 mg/kg BID induced precocious deaths in 1/6 Balb/c and 2/6 uPA-transgenic mice. Apart 
from a non-persistent clinical inactivity, the remaining animals tolerated BILN2061-dosing well. 
Compared to previous oral dosing studies, plasma BILN2061 trough levels were similar after 30 
mg/kg BID, but almost 20-fold higher after 150 mg/kg BID. Profound electrocardiographic 
changes were documented in the J-waves corresponding to the ventricular repolarisation in all 
mice treated with 150mg/kg. In Balb/c (n=3) and SCID (n=4) mice an increase in the height and 
surface area of the J wave was observed, while in uPA-transgenic SCID mice (n=4) BILN2061 
dosing induced an elongation of the J-wave without increasing its height. ECG-changes were 
apparent within 30 minutes after a single dose and recuperated after 6 hours. The 30mg/kg dose 
induced similar but less pronounced ECG-changes. In selected animals, heart samples showed 
similar ultrastructural mitochondrial defects as previously described. No apparent defects in the 
oxidative phosporylation activity could be documented. We are currently analyzing the ECG-
kinetic changes with sequentially obtained plasma samples to determine a PK-PD threshold. 
Conclusion:  The HCV NS3-protease inhibitor BILN2061 induces mitochondrial cardiotoxicity in 
mice and is associated with specific, rapid but transient electrocardiograohic changes in the 
ventricular repolarisation wave. As other HCV NS3 inhibitors have been associated with 
preclinical cardiotoxicity, more extensive studies on the pathophysiological mechanisms are 
warranted to be able to early detect any class toxicity. 
 
